RemAb Therapeutics: an alternative drug against hospital infections
RemAb Therapeutics: an alternative drug against hospital infections and that stimulates the immune system as an alternative to the use of antibiotics.
The resistance to antibiotics that some bacteria develop is a serious health problem. In Europe alone, hospital infections cause up to 25,000 deaths a year. The spin-off RemAb Therapeutics, belonging to the Bellvitge Biomedical Research Institute and the Bellvitge University Hospital, is developing a drug as an alternative to the use of antibiotics. According to Rafael Máñez, founder of this biotechnology company, 70% of patients admitted to the ICU for more than 7 days end up developing hospital infections caused largely by Gram-negative bacteria, which are resistant to antibiotics.
The new drug designed by RemAb Therapeutics stimulates the immune system. Dr. Máñez's group has developed a molecule that allows to selectively eliminate the antibodies used by these bacteria to protect themselves. The drug binds specifically to antibodies without bactericidal capacity, so that it would be possible to attack these infections avoiding the generation of new resistance.
This project has already attracted the attention of investors. You have been selected by the CaixaImpulse Consolidate program and you will receive aid of up to 300,000 euros, as well as personalized support in the transfer process to the market. The CaixaImpulse program was created 5 years ago with the aim of facilitating the transfer of scientific knowledge to society. According to Dr. Máñez, clinical trials are expected to begin next year 2021.